MedTrace Logo

Luteal Phase Support In IVF Women Using GnRH Agonist

NCT04174378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2019-11-25

No results posted yet for this study

Summary

Lately, the role of GnRH agonist as luteal phase support has been recommended by various studies though the mechanism is still debatable. It has been postulated that GnRH agonist might support the corpus luteum by stimulating the secretion of luteinizing hormone by pituitary gonadotroph cells, or by acting directly on the endometrium through the locally expressed receptors.

Therefore, this study was designed to evaluate effects of the additional of single-dose GnRH agonist to the routine progestogens use for luteal phase support on IVF outcome as compared to progestogens only. The biochemical pregnancy rates, clinical pregnancy rates, live birth rates and miscarriage rate between these regimes were compared. The hypothesis of this study was women with addition of GnRH agonist as luteal phase support have higher biochemical pregnancy rate, clinical pregnancy rate and live birth rate compare to patient with progestogens only luteal phase support.

Conditions

  • IVF
  • Luteal Phase Defect

Interventions

DRUG

Decapeptyl 0.2mg

IM Decapeptyl o.2 mg was given 2 days before embryo transfer

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Muhammad Azrai Abu, Medical Degree · Department of Obstetrics and Gynecology, UKM Medical Centre

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-29
Primary Completion
2019-08-28
Completion
2019-11-18
FDA Drug
Yes

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174378 on ClinicalTrials.gov